Therapeutic vitamin d sun-protecting formulations and methods for their use

Abstract

The present invention concerns topical sun-protecting formulations including therapeutically effective amounts of Vitamin D, including formulations that provide Vitamin D in bioavailable amounts that correspond to decreased natural Vitamin D production resulting from the sun-blocking effects of the formulations and formulations for the prevention and treatment of disorders and disease states associated with vitamin D deficiency and vitamin D insufficiency.

1 . (canceled) 
     
     
         2 . A therapeutic sun-protecting composition according to  claim 35 , wherein said at least one vitamin D compound is present in an amount to compensate for a reduction in said mammal's vitamin D production. 
     
     
         3 . A therapeutic sun-protecting composition according to  claim 35 , wherein said mammal has a vitamin D deficiency or has a vitamin D insufficiency. 
     
     
         4 . A therapeutic sun-protecting composition according to  claim 3 , wherein said mammal has a serum (25-hydroxy) vitamin D concentration of less than about 20 ng/mL; of less than about 30 ng/mL; of less than about 40 ng/mL; or of less than about 50 ng/mL. 
     
     
         5 . A therapeutic sun-protecting composition according to  claim 35 , wherein administration of said at least one vitamin D compound to said mammal results in a serum (25-hydroxy) vitamin D concentration in said mammal in a range of about 20 ng/mL to about 100 ng/mL. 
     
     
         6 . A therapeutic sun-protecting composition according to  claim 35 , wherein said at least one vitamin D compound is present in said therapeutic sun-protecting composition at a concentration that results in administration of said at least one vitamin D compound to the skin of said mammal at a concentration of about 0.1 IU/cm 2  to about 1000 IU/cm 2  or at a concentration of about 0.1 IU/cm 2  to about 10.0 IU/cm 2 . 
     
     
         7 . (canceled) 
     
     
         8 . A therapeutic sun-protecting composition according to  claim 35 , wherein said at least one sun-protecting agent is selected from the group consisting of aminobenzoic acid, avobenzone, benzophenone, benzophenone-3, cinnamates, cinoxate, dioxybenzone, ecamsule, ensulizole, ethylhexyl p-methoxycinnamate, homosalate, menthyl anthranilate, meradimate, octinoxate, octisalate, octocrylene, octyl dimethyl paba, octyl methoxycinnamate (OMC), octyl salicytate (OCS), oxybenzone, padimate-O, para-aminobenzoic acid (PABA), Parsol® 1789, salicylates, sulisobenzone, sulisobenzone, titanium dioxide, trolamine salicylate, and zinc oxide. 
     
     
         9 . A therapeutic sun-protecting composition according to  claim 35 , wherein said at least one vitamin D compound is selected from the group consisting of vitamin D 2  (ergocalciferol), vitamin D 3  (cholecalciferol), vitamin D precursors, inactive forms, active forms, and metabolites thereof. 
     
     
         10 . A therapeutic sun-protecting composition according to  claim 35 , wherein said at least one sun-protecting agent, said at least one vitamin D compound, and said pharmaceutical carrier are provided in combination in the form of a cream, gel, liquid, lotion, solution, spray, emulsion, aerosol, or a combination thereof. 
     
     
         11 . A therapeutic sun-protecting composition according to  claim 35 , wherein said pharmaceutically effective carrier is selected from the group consisting of water, alcohol, other oil-free carriers, or mixtures thereof. 
     
     
         12 . A therapeutic sun-protecting composition according to  claim 35 , further comprising one or more of the following: at least one emollient; at least one skin condition agent; at least one humectant; at least one emulsifying agent; at least one conditioning agent; at least one stabilizing agent; at least one thickening agent; at least one antioxidant; at least one UV stabilizer; and at least one UV radiation absorber. 
     
     
         13 . A therapeutic sun-protecting composition according to  claim 12 , wherein (a) said at least one emollient is selected from the group consisting of fatty esters, fatty alcohols, mineral oils, polyether siloxane copolymers, polypropylene glycol (“PPG”)-15 stearyl ether, PPG-10 acetyl ether, steareth-10, oleth-8, PPG-4 lauryl ether, vitamin E acetate, PEG-7 glyceryl cocoate, lanolin, cetyl alcohol, octyl hydroxystearate, dimethicone, cetyl alcohol, octyl hydroxystearate, dimethicone, derivatives, combinations, and mixtures thereof (b) said at least one skin condition agent is selected from the group consisting of colloidal oatmeal, olive leaf, sulfonated shale oil, elubiol, 6-(1-piperidinyl)-2,4-pyrimidinediamine-3-oxide finasteride, ketoconazole, zinc pyrithione, coal tar, benzoyl peroxide, selenium sulfide, hydrocortisone, pramoxine hydrochloride, tricetylammonium chloride, polyquaternium 10, panthenol, panthenol triacetate, vitamin B, vitamin C, vitamin D, vitamin E, vitamin K, keratin, lysine, arginine, hydrolyzed wheat proteins, hydrolyzed silk proteins, octyl methoxycinnamate, oxybenzone, minoxidil, titanium dioxide, zinc dioxide, erthromycin, tretinoin, derivatives, combinations, and mixtures thereof; (c) said least one humectant is a polyhydric alcohol selected from the group consisting of glycerol/glycerin, polyalkylene glycols, alkylene polyols, including butylene glycol, propylene glycol, dipropylene glycol, polypropylene glycol, and polyethylene glycol, sorbitol, hydroxypropyl sorbitol, hexylene glycol, 1,3-dibutylene glycol, 1,2,6-hexanetriol ethoxylated glycerol, propoxylate glycerol, derivatives, combinations, and mixtures thereof; (d) said at least one emulsifying agent is selected from the group consisting of polysorbitate 80, glyceryl distearate, POE 10 stearyl ether, ceateareth 20, stearyl alcohol, ceteareth 20, cetearyl alcohol, POE 2 stearyl ether, other oil-free emulsifying agents, derivatives, combinations, and mixtures thereof; (e) said at least one conditioning agent is selected from the group consisting of octyl hydroxystearate; emollients, such as cholesterol NF, petrolatum, mineral oils and esters, including isopropyl myristate, isopropyl palmitate, 1-decene polymer (hydrogenated), and C 12 -C 15  alcohol benzoates, tocopherol, tocotrienol, and derivatives, combinations, and mixtures thereof; (f) said at least one stabilizing agent is selected from the group consisting of butylated hydroxy toluene (BHT), ethylene diamine tetra acetic acid (EDTA), triethanolamine (TEA), glycerin, propylene glycol, derivatives, combinations, and mixtures thereof; (g) said at least one thickening agent is selected from the group consisting of polyacrylamide, C 13 -C 14  isoparafin, laureth-7, and derivatives, combinations, and mixtures thereof; and (h) said at least one antioxidant is selected from the group consisting of ascorbic acid, ascorbyl palmitate, BHT, tocopheryl acetate, butylated hydroanisole (BHA), phenyl-α-naphthylamine, hydroquinone, propyl gallate, nordihydroquiaretic acid, Garcinia Mangostana (Mangosteen) Peel Extract  Camellia Sinensis  (Green and White Tea) Leaf Extract,  Punica Granatum  (Pomegranate) Extract, tocopherol, tocotrienol, and derivatives, combinations, and mixtures thereof. 
     
     
         14 . (canceled) 
     
     
         15 . (canceled) 
     
     
         16 . (canceled) 
     
     
         17 . (canceled) 
     
     
         18 . (canceled) 
     
     
         19 . (canceled) 
     
     
         20 . (canceled) 
     
     
         21 . (canceled) 
     
     
         22 . (canceled) 
     
     
         23 . (canceled) 
     
     
         24 . (canceled) 
     
     
         25 . (canceled) 
     
     
         26 . (canceled) 
     
     
         27 . (canceled) 
     
     
         28 . (canceled) 
     
     
         29 . (canceled) 
     
     
         30 . A method of preventing disorders and diseases associated with vitamin D deficiency or vitamin D insufficiency, comprising topically administering to a mammal a therapeutic sun-protecting composition according to  claim 35 . 
     
     
         31 . A method of preventing disorders and diseases associated with vitamin D deficiency or vitamin D insufficiency according to  claim 30 , wherein said therapeutic sun-protecting composition is topically administered to said mammal in a single application, or is topically administered to said mammal in multiple applications. 
     
     
         32 . A method of treating disorders and diseases associated with vitamin D deficiency or vitamin D insufficiency, comprising topically administering to a mammal having at least one disorder or disease associated with vitamin D deficiency a therapeutic sun-protecting composition according to  claim 35 . 
     
     
         33 . A method of treating disorders and diseases associated with vitamin D deficiency or vitamin D insufficiency according to  claim 32 , wherein said at least one disorder or disease state associated with vitamin D deficiency or vitamin D insufficiency is selected from the group consisting of disorders and diseases associated with low calcium uptake, bone-related disorders and diseases, malabsorption-related disorders and diseases, vascular disorders and diseases, autoimmune disorders and diseases, tuberculosis, periodontal disease, chronic pain, seasonal affective disorder, cognitive impairment, depression, type I diabetes, chronic renal disease, hypoparathyroid, Parkinson's disease, and cancer. 
     
     
         34 . A method of treating disorders and diseases associated with vitamin D deficiency or vitamin D insufficiency according to  claim 32 , wherein said therapeutic sun-protecting composition is topically administered to said mammal in a single application, or is topically administered to said mammal in multiple applications. 
     
     
         35 . A therapeutic sun-protecting composition, comprising: (a) at least one sun-protecting agent; (b) at least one vitamin D compound, said vitamin D compound being present in a therapeutically effective amount such that, upon topical administration to a mammal, said vitamin D compound is absorbed through the skin of said mammal and causes a measurable increase in said mammal's serum vitamin D levels; and (c) a pharmaceutical carrier effective for topical administration of said at least one sun-protecting agent and said at least one vitamin D compound, wherein said vitamin D compound is separated from said sun-protecting agent within said therapeutic sun-protecting composition. 
     
     
         36 . A therapeutic sun-protecting composition according to  claim 35 , wherein said at least one vitamin D compound is a physiologic biological vitamin D compound. 
     
     
         37 . A therapeutic sun-protecting composition according to  claim 35 , wherein said vitamin D compound is capable of being absorbed through the skin of said mammal and cause a measurable increase in said mammal's serum vitamin D levels in the absence of an alcohol carrier. 
     
     
         38 . A therapeutic sun-protecting composition according to  claim 35 , wherein said separation of said vitamin D compound from said sun-protecting agent results from encapsulation of said vitamin D compound within said therapeutic sun-protecting composition. 
     
     
         39 . A therapeutic sun-protecting composition according to  claim 35 , wherein said separation of said vitamin D compound from said sun-protecting agent results from a difference in the solubility of said vitamin D compound in said pharmaceutical carrier and the solubility of said sun-protecting agent in said pharmaceutical carrier. 
     
     
         40 . A therapeutic sun-protecting composition according to  claim 35 , wherein said separation of said vitamin D compound from said sun-protecting agent results from said vitamin D compound and said sun-protecting agent being in separate phases within said therapeutic sun-protecting composition. 
     
     
         41 . A therapeutic sun-protecting composition according to  claim 40 , wherein said separate phases include a relatively lipophilic phase and a relatively hydrophilic phase. 
     
     
         42 . A therapeutic sun-protecting composition according to  claim 35 , wherein said separation of said vitamin D compound from said sun-protecting agent results from chemical binding of said vitamin D compound and/or said sun-protecting agent to said pharmaceutical carrier. 
     
     
         43 . A therapeutic sun-protecting composition according to  claim 35 , further comprising a second pharmaceutical carrier effective for topical administration of the other of said at least one sun-protecting agent and said at least one vitamin D compound that is delivered by said pharmaceutical carrier effective for topical administration of said at least one sun-protecting agent and said at least one vitamin D compound. 
     
     
         44 . A therapeutic sun-protecting formulation prepared by a process comprising the steps of: (a) providing a therapeutically effective amount of a vitamin D compound: (b) providing a pharmaceutical carrier effective for topical administration of said vitamin D compound, said pharmaceutical carrier being capable of delivering said vitamin D compound to a mammal to cause a measurable increase in said mammal's serum vitamin D levels while decreasing the exposure of said mammal's skin to UV radiation, wherein said pharmaceutical carrier is capable of delivering said vitamin D compound to cause a measurable increase in said mammal's serum vitamin D levels in the absence of alcohol; and (c) mixing said vitamin D compound and said pharmaceutical carrier. 
     
     
         45 . A therapeutic sun-protecting composition, comprising: (a) at least one sun-protecting agent; (b) at least one vitamin D compound, said vitamin D compound being present in a therapeutically effective amount such that, upon topical administration to a mammal, said vitamin D compound is absorbed through the skin of said mammal and causes a measurable increase in said mammal's serum vitamin D levels; and (c) a pharmaceutical carrier effective for topical administration of said at least one sun-protecting agent and said at least one vitamin D compound, wherein said vitamin D compound is capable of being absorbed through the skin of said mammal and cause a measurable increase in said mammal's serum vitamin D levels in the absence of an alcohol carrier. 
     
     
         46 . A therapeutic sun-protecting composition, comprising: (a) at least one sun-protecting agent capable of absorbing ultraviolet radiation; (b) at least one therapeutic vitamin D compound; and (c) a pharmaceutical carrier, wherein, upon topical administration of said therapeutic sun-protecting composition to a mammal, said pharmaceutical carrier simultaneously delivers (i) said therapeutic vitamin D compound through the skin and into the bloodstream of said mammal to cause a measurable increase in said mammal's serum vitamin D levels; and (ii) said sun-protecting agent to the surface of the skin of said mammal.